Colorectal

Cancer Clinical Trials: How New Search Tools Make It Easier For Patients To Find The Treatment They Need

(Newsweek) July 20, 2017 - A cancer patient’s project grew into the Late-Stage MSS-CRC Trial Finder, launched in May in partnership with the advocacy organization Fight CRC and the health care technology company Flatiron Health. It offers patients and caregivers a curated list of trials for which they might be eligible.

read article

With Cancer Screening, Better Safe Than Sorry?

(New York Times/Well blog) July 17, 2017 - Many patients, no matter how old or sick they may be, are reluctant to abandon tests they’ve long been told can be lifesaving.

read article

ODAC Gives Its Seal Of Approval To Two More Biosimilars

(BioWorld Online) July 13, 2017 - Despite struggling with extrapolation, the FDA's Oncologic Drugs Advisory Committee (ODAC) unanimously supported approval of two biosimilars referencing Roche Holding AG's Avastin and Herceptin.

read article

Cancer May Metastasize Without Lymph Node Involvement

(National Foundation for Cancer Research) July 13, 2017 - Research has provided the first evidence that the century old model for cancer metastasis - where cancer spreads from primary tumor, to nearby lymph nodes, and then to other organs - may not apply in all cases.

read press release

Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)

(Morningstar) July 13, 2017 - Amgen and Allergan plc. today announced that the Companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). ABP 215 is a biosimilar candidate to Avastin® (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

read article

Eyeing Recent FDA Decision, Promega to Seek Approvals for MSI Assay

(Xconomy Wisconsin) July 10, 2017 - Laboratory supplies company Promega wants its tests to join the decision-making tools that clinicians use when treating patients and the Fitchburg, WI company now plans to seek the necessary approvals for use of one its tests in colorectal cancer.

read article

Insurance Coverage for CT Colonography Increases Likelihood of Screening

(RSNA) July 11, 2017 - People with insurance policies that cover CT colonography for colorectal cancer screening are almost 50 percent more likely to get screened than those whose policies don’t cover the procedure, according to a new study appearing online in the journal Radiology.

read press release

Cleveland Clinic Researchers Publish New Findings on Influence of High-Fat Diet on Colorectal Cancer

(Cleveland Clinic) July 6, 2017 - Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known.

read press release

Lymph Nodes Not Responsible for All Distant Metastases in CRC

(Medscape Medical News) July 6, 2017 - The long-standing assumption that distant metastases arise from lymph node metastases is being challenged by new research suggesting that distant metastases may come directly from the primary tumor itself, at least in colorectal cancer (CRC), researchers report.

read article (free registration required)

World GI 2017 Press Release: Right-sided Colorectal Tumours: An Internal Radiation Advantage

(ESMO) July 1, 2017 - For patients with colorectal cancer that has metastasized to the liver, having a primary tumour on the left side, as opposed to the right side of the colon, is known to be a significant advantage in terms of treatment response.

read press release

FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer

(Amgen) June 29, 2017 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Vectibix® (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

read corporate press release

Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit

(Yahoo! Finance) June 29, 2017 - Illumina, Inc. today announced its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit that meets the newly published guidelines for evaluation of colorectal cancer from the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO)1.

read article

CEA Blood Test Improves Stratification in Colon Cancer

(Medscape Medical News) June 28, 2017 - Patients with stage II colon cancer whose carcinoembryonic antigen (CEA) level is elevated should receive chemotherapy in addition to surgery, Mayo Clinic researchers advise.

read article (free registration required)

MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers

(MabVax Therapeutics) June 27, 2017 - MabVax Therapeutics Holdings, Inc. today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MVT-1075, the Company's fully human antibody radioimmunotherapy (RIT), for the treatment of CA19-9 positive malignancies including pancreatic, colon and lung cancers.

read corporate press release

Fight Colorectal Cancer Launches Biomarked to Educate on the Role of Biomarkers in Cancer Treatment

(Yahoo! Finance) June 27, 2017 - Today, Fight Colorectal Cancer (Fight CRC), the leading patient advocacy group in colorectal cancer, kicked-off Biomarked, with support from Eli Lilly and Company, to shine a spotlight on genetic biomarkers and the critical role they can play in colorectal cancer treatment.

read article

Underused Cancer Test Could Improve Treatment For Thousands, Mayo Clinic Study Finds

(Mayo Clinic) June 21, 2017 - A simple blood test could improve treatment for more than 1 in 6 stage 2 colon cancer patients, suggests new Mayo Clinic research. The researchers also discovered that many patients who could benefit from the test likely aren’t receiving it. The findings were published in the Journal of Gastrointestinal Surgery.

read press release

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer

(eFFECTOR Therapeutics) June 20, 2017 – eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).

read corporate press release

Celyad Reports Impressive Preliminary CAR-T Results in Solid Tumors

(Labiotech.eu) June 19, 2017 - Celyad has announced no toxicity and stable disease in colorectal cancer patients after just 3 months of its first trial testing CAR-T in solid tumors.

read article

Researchers Develop First-Ever Human Tissue Platform to Test Drugs for Colon Cancer

(Weill Cornell Medicine) June 19, 2017 - The first-ever “disease in a Petri dish” platform that models human colon cancer derived from stem cells has been developed by Weill Cornell Medicine investigators, allowing them to identify a targeted drug treatment for a common, inherited form of the disease.

read article

New Web Calculator to More Accurately Predict Bowel Cancer Survival

(University of Nottingham [UK]) June 16, 2017 - While current methods of estimating mortality can be crude, patients with bowel cancer could soon more accurately predict their chances of survival, thanks to a new web calculator developed by academics at The University of Nottingham and medical software company ClinRisk Ltd.

read press release
Next Page